Medicine
Tepezza 500 mg powder for injection
Tepezza 500 mg powder for injection is a prescription medicine containing Teprotumumab for intravenous use, marketed by Horizon Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton until time of use…
Key facts
- Active ingredient (INN)
- Teprotumumab
- Brand
- Tepezza
- Strength
- 500 mg
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- Horizon Therapeutics
- Manufacturer
- Horizon Therapeutics
- Origin register
- US FDA, United States
- Storage
- Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton until time of use to protect from light. Do not freeze.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AG13 Teprotumumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 January 2020
- Identifiers
- RxCUI 2274807, 2274812DailyMed set ID 3e6c54a1-cefd-4a5b-a855-ab9f268b6cceNDC 75987-130Application BLA761143
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial, single-dose | 75987-130-15 | Horizon Therapeutics | 21 January 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Teprotumumab is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. It is available as powder for injection for intravenous use. MedsAcross supplies Teprotumumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TeprotumumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TEPEZZA prescribing information (Horizon Therapeutics) · U.S. National Library of Medicine, DailyMed
- Tepezza: European public assessment report (EPAR) · European Medicines Agency
Need Tepezza 500 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.